OBJECTIVES: To identify host and viral characteristics associated with long-term persisting low-level viraemia (PLLV) under antiretroviral therapy (ART). PATIENTS AND METHODS: Seventy-one ART-treated patients with long-term PLLV (20-250 copies/mL) and 102 control patients with systematically undetectable viral load (VL) were selected retrospectively from ART-treated patients followed at the Ghent HIV reference centre. Host and viral characteristics were compared using univariate and multivariate analyses. RESULTS: Higher plasma VL at therapy initiation (OR 3.52; 95% CI 1.86-6.65; P < 0.001), therapy re-initiation after an interruption (OR 3.94; 95% CI 1.70-9.16; P = 0.001), male gender (OR 4.28; 95% CI 1.40-13.00; P = 0.011), a protease inhibitor-based regimen (OR 2.90; 95% CI 1.20-6.97; P = 0.017) and predicted CCR5 co-receptor tropism (OR 2.53; 95% CI 1.05-6.11; P = 0.039) were independently associated with PLLV. CONCLUSIONS: VL at ART initiation, therapy history, gender, ART regimen and co-receptor tropism were independently associated with PLLV. Gender, therapy history, co-receptor tropism and VL at ART initiation could be valuable predictive markers to identify patients at risk for PLLV.
OBJECTIVES: To identify host and viral characteristics associated with long-term persisting low-level viraemia (PLLV) under antiretroviral therapy (ART). PATIENTS AND METHODS: Seventy-one ART-treated patients with long-term PLLV (20-250 copies/mL) and 102 control patients with systematically undetectable viral load (VL) were selected retrospectively from ART-treated patients followed at the Ghent HIV reference centre. Host and viral characteristics were compared using univariate and multivariate analyses. RESULTS: Higher plasma VL at therapy initiation (OR 3.52; 95% CI 1.86-6.65; P < 0.001), therapy re-initiation after an interruption (OR 3.94; 95% CI 1.70-9.16; P = 0.001), male gender (OR 4.28; 95% CI 1.40-13.00; P = 0.011), a protease inhibitor-based regimen (OR 2.90; 95% CI 1.20-6.97; P = 0.017) and predicted CCR5 co-receptor tropism (OR 2.53; 95% CI 1.05-6.11; P = 0.039) were independently associated with PLLV. CONCLUSIONS: VL at ART initiation, therapy history, gender, ART regimen and co-receptor tropism were independently associated with PLLV. Gender, therapy history, co-receptor tropism and VL at ART initiation could be valuable predictive markers to identify patients at risk for PLLV.
Authors: H Melliez; A Duhamel; O Robineau; L Bocket; I Kim; E Sauser; F Loiseleur; N Viget; A Pasquet; E Senneville; D Seguy Journal: Eur J Clin Microbiol Infect Dis Date: 2017-06-24 Impact factor: 3.267
Authors: Hanna Brattgård; Per Björkman; Piotr Nowak; Carl Johan Treutiger; Magnus Gisslén; Olof Elvstam Journal: PLoS One Date: 2022-05-17 Impact factor: 3.240
Authors: Gisela Leierer; Katharina Grabmeier-Pfistershammer; Andrea Steuer; Mario Sarcletti; Maria Geit; Bernhard Haas; Ninon Taylor; Manfred Kanatschnig; Michaela Rappold; Bruno Ledergerber; Robert Zangerle Journal: Open Forum Infect Dis Date: 2016-06-15 Impact factor: 3.835
Authors: Olof Elvstam; Gaetano Marrone; Patrik Medstrand; Carl Johan Treutiger; Veronica Svedhem; Magnus Gisslén; Per Björkman Journal: Open Forum Infect Dis Date: 2021-03-17 Impact factor: 3.835
Authors: Jonathan Z Li; Evgenia Aga; Ronald J Bosch; Mark Pilkinton; Eugène Kroon; Lynsay MacLaren; Michael Keefer; Lawrence Fox; Liz Barr; Edward Acosta; Jintanat Ananworanich; Robert Coombs; John W Mellors; Alan L Landay; Bernard Macatangay; Steven Deeks; Rajesh T Gandhi; Davey M Smith Journal: Clin Infect Dis Date: 2022-03-09 Impact factor: 20.999
Authors: Gisela Leierer; Katharina Grabmeier-Pfistershammer; Andrea Steuer; Maria Geit; Mario Sarcletti; Bernhard Haas; Manfred Kanatschnig; Michaela Rappold; Robert Zangerle; Bruno Ledergerber; Ninon Taylor Journal: PLoS One Date: 2015-11-13 Impact factor: 3.240